Sean Brynjelsen - Net Worth and Insider Trading

Sean Brynjelsen Net Worth

The estimated net worth of Sean Brynjelsen is at least $4 Million dollars as of 2024-05-10. Sean Brynjelsen is the CEO of Eton Pharmaceuticals Inc and owns about 1,064,940 shares of Eton Pharmaceuticals Inc (ETON) stock worth over $4 Million. Details can be seen in Sean Brynjelsen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Sean Brynjelsen has not made any transactions after 2022-09-22 and currently still holds the listed stock(s).

Transaction Summary of Sean Brynjelsen

To

Sean Brynjelsen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Sean Brynjelsen owns 2 companies in total, including Eton Pharmaceuticals Inc (ETON) , and Sagent Pharmaceuticals Inc (SGNT) .

Click here to see the complete history of Sean Brynjelsen’s form 4 insider trades.

Insider Ownership Summary of Sean Brynjelsen

Ticker Comapny Transaction Date Type of Owner
ETON Eton Pharmaceuticals Inc 2022-09-22 director & President & CEO
SGNT Sagent Pharmaceuticals Inc 2016-08-29 EVP & Business Development

Sean Brynjelsen Latest Holdings Summary

Sean Brynjelsen currently owns a total of 1 stock. Sean Brynjelsen owns 1,064,940 shares of Eton Pharmaceuticals Inc (ETON) as of September 22, 2022, with a value of $4 Million.

Latest Holdings of Sean Brynjelsen

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ETON Eton Pharmaceuticals Inc 2022-09-22 1,064,940 3.40 3,620,796

Holding Weightings of Sean Brynjelsen


Sean Brynjelsen Form 4 Trading Tracker

According to the SEC Form 4 filings, Sean Brynjelsen has made a total of 5 transactions in Eton Pharmaceuticals Inc (ETON) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Eton Pharmaceuticals Inc is the acquisition of 10,000 shares on September 22, 2022, which cost Sean Brynjelsen around $21,000.

Insider Trading History of Sean Brynjelsen

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Sean Brynjelsen Trading Performance

GuruFocus tracks the stock performance after each of Sean Brynjelsen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Sean Brynjelsen is 0.86%. GuruFocus also compares Sean Brynjelsen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Sean Brynjelsen within 3 months outperforms 2 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Sean Brynjelsen's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Sean Brynjelsen

Average Return

Average return per transaction

Outperforming Transactions

2 out of 6 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 0
Relative Return to S&P 500(%) -0.47

Sean Brynjelsen Ownership Network

Ownership Network List of Sean Brynjelsen

No Data

Ownership Network Relation of Sean Brynjelsen


Sean Brynjelsen Owned Company Details

What does Eton Pharmaceuticals Inc do?

Who are the key executives at Eton Pharmaceuticals Inc?

Sean Brynjelsen is the director & President & CEO of Eton Pharmaceuticals Inc. Other key executives at Eton Pharmaceuticals Inc include Chief Business Officer David Krempa , Chief Financial Officer James R. Gruber , and 10 percent owner Opaleye Management Inc. .

Eton Pharmaceuticals Inc (ETON) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eton Pharmaceuticals Inc (ETON) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eton Pharmaceuticals Inc (ETON) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eton Pharmaceuticals Inc (ETON)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Eton Pharmaceuticals Inc Insider Transactions

No Available Data

Sean Brynjelsen Mailing Address

Above is the net worth, insider trading, and ownership report for Sean Brynjelsen. You might contact Sean Brynjelsen via mailing address: C/o Eton Pharmaceuticals, Inc., 21925 W Field Pkwy #235, Deer Park Il 60010.

Discussions on Sean Brynjelsen

No discussions yet.